A Strategic Shift Eases Investor Concerns for Hims & Hers

Hims & Hers stock stabilizes as a patent settlement with Novo Nordisk removes regulatory risk, despite near-term margin pressure from a shift to branded weight-loss drugs.

Investor sentiment toward the telehealth platform Hims & Hers is showing signs of recovery following a volatile March marked by significant share price declines. The catalyst for this renewed confidence is somewhat counterintuitive: while future profit margins are expected to face pressure, the resolution of a major legal overhang is removing a substantial layer of risk. A recently settled dispute with pharmaceutical titan Novo Nordisk is prompting a strategic pivot that analysts believe will create a more sustainable long-term business foundation.

Regulatory Clarity Through Settlement

Market relief was evident in a recent share price stabilization, with the equity advancing by two percent on Monday. This follows a crucial development in early March, when Hims & Hers reached an agreement to settle a contentious patent litigation with Novo Nordisk. The resolution mandates the discontinuation of the company's controversial, self-compounded semaglutide offerings. Moving forward, the platform will officially distribute the approved brand-name medications, Wegovy and Ozempic.

Market experts view this strategic exit favorably. Although the move away from compounded alternatives is projected to weigh on gross margins, it effectively eliminates the persistent threat of regulatory clashes with U.S. federal authorities. This shift aligns the company's operations with more stringent regulatory standards.

Growth Initiatives Amid an Attractive Valuation

This strategic realignment coincides with positive regulatory developments. Just last week, the U.S. Food and Drug Administration granted approval for a higher-dose version of Wegovy. Hims & Hers promptly integrated both injectable and oral variants of the medication into its digital healthcare ecosystem.

Concurrently, management is aggressively pursuing international growth. The planned acquisition of Eucalyptus for up to $1.15 billion is designed to establish a foothold in key markets, including Australia and Japan. Despite these ambitious expansion efforts, the company's shares are currently valued at just 1.7 times expected sales. This stands in stark contrast to the industry average for health information services, which commands a nearly double valuation multiple of 3.3.

Near-Term Headwinds and Long-Term Vision

For the full fiscal year 2026, market consensus projects revenue in the range of $2.7 to $2.9 billion. Investors should note, however, an anticipated near-term headwind of approximately $65 million in the first quarter, related to the reorganization of the company's logistics centers.

The precise impact of the transition to branded medications on profitability will become clearer on May 11, 2026. On that date, Hims & Hers is scheduled to report its first-quarter results and provide an update on subscriber growth, which had already surpassed the 2.5 million mark by the end of 2025. These figures will serve as the next critical benchmark on the company's path toward its long-term ambition of achieving $6.5 billion in annual revenue by 2030.